Department of Obstetrics and Gynecology, Jundiaí School of Medicine, Jundiaí, São Paulo, Brazil.
Contraception. 2010 Mar;81(3):215-22. doi: 10.1016/j.contraception.2009.10.010. Epub 2009 Nov 22.
The objective of this study was to compare bleeding patterns of women using a contraceptive combination of 30 mcg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) continuously or cyclically. Menstrual-related symptoms were also evaluated.
This open, prospective, randomized study evaluated 78 women using the EE/DRSP combination continuously for 168 days or for six 28-day cycles, each followed by a 7-day hormone-free interval. A diary with pre-established scales was used to assess the frequency and intensity of bleeding and menstrual-related symptoms.
Amenorrhea increased with continuous use; 62.2% of women with continuous use were amenorrheic at the end of treatment (95% CI: 46.6-77.8%). Dysmenorrhea, headache, acne, nausea, edema and increased appetite improved significantly in the continuous-use group, and mastalgia and edema in the cyclic-use group (p<.05). Six subjects in the continuous-use group (15.4%) and three in the cyclic-use group (7.7%) discontinued due to adverse events.
Continuous use was associated with amenorrhea and fewer menstrual-related symptoms compared to cyclic use.
本研究旨在比较连续或周期性使用含 30 微克炔雌醇（EE）和 3 毫克屈螺酮（DRSP）的复方避孕药的女性出血模式。同时也评估了与月经相关的症状。
本开放性、前瞻性、随机研究评估了 78 名连续使用 EE/DRSP 复方避孕药 168 天或连续使用 6 个 28 天周期的女性，每个周期后有 7 天的无激素间隔。使用带有预先设定量表的日记评估出血和与月经相关的症状的频率和强度。
连续使用导致闭经增加；连续使用组治疗结束时闭经的女性占 62.2%（95%CI：46.6-77.8%）。在连续使用组中，痛经、头痛、痤疮、恶心、水肿和食欲增加显著改善，而在周期性使用组中，乳房触痛和水肿也有所改善（p<.05）。连续使用组中有 6 名受试者（15.4%）和周期性使用组中有 3 名受试者（7.7%）因不良事件而停药。
与周期性使用相比，连续使用与闭经和较少的月经相关症状相关。
